Evidence map›Paper›PMID 29263873›Full record

ArticleNPJ vaccines2017

Protection against inhalation anthrax by immunization with

B Kim Lee Sim, Minglin Li, Manuel Osorio, Yun Wu, Tint T Wai, Johnny W Peterson, Eric R James, Sumana Chakravarty, Lixin Gao, Rui Xu and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Disrupting vaccine logistics.International health · 2021
    Article
  6. Article
  7. Zoonoses under our noses.Microbes and infection
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

B Kim Lee SimProtein Potential LLC, Rockville, MD 20850 USA.
Minglin LiProtein Potential LLC, Rockville, MD 20850 USA.
Manuel OsorioU.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Silver Spring, MD 20993 USA.
Yun WuProtein Potential LLC, Rockville, MD 20850 USA.
Tint T WaiProtein Potential LLC, Rockville, MD 20850 USA.
Johnny W PetersonDepartment of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 USA.
Eric R JamesSanaria Inc, Rockville, MD 20850 USA.
Sumana ChakravartySanaria Inc, Rockville, MD 20850 USA.
Lixin GaoProtein Potential LLC, Rockville, MD 20850 USA.
Rui XuProtein Potential LLC, Rockville, MD 20850 USA.
Natasha KcProtein Potential LLC, Rockville, MD 20850 USA.
Richard E StaffordProtein Potential LLC, Rockville, MD 20850 USA.
William S LawrenceDepartment of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 USA.
Linsey A YeagerDepartment of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 USA.
Jennifer E PeelDepartment of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 USA.
Satheesh K SivasubramaniDepartment of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 USA.
Ashok K ChopraDepartment of Microbiology and Immunology, Galveston National Laboratory, Center for Biodefense and Emerging Infectious Diseases, and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 USA.
Svetlana FilippovaU.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Silver Spring, MD 20993 USA.
Stephen L HoffmanProtein Potential LLC, Rockville, MD 20850 USA.
Protein Potential (United States) · USThe University of Texas Medical Branch at Galveston · USSanaria · USCenter for Biologics Evaluation and Research · USUnited States Food and Drug Administration · US

Funding

Development of Enabling Vector/Antigen Expression Technology for an Orally-DeliveR01AI098884 · NIAID · PROTEIN POTENTIAL, LLC · PI SIM, B. KIM LEE · 2012 to 2016
$5.8M
Live Attenuated Oral Anthrax VaccineR43AI091273 · NIAID · PROTEIN POTENTIAL, LLC · PI SIM, B. KIM LEE · 2010 to 2011
$600k
NIAID NIH HHS R01 AI098884NIAID NIH HHS R43 AI091273
6 · The paper itself

Abstract

The national blueprint for biodefense concluded that the United States is underprepared for biological threats. The licensed anthrax vaccine absorbed vaccine, BioThrax, requires administration of at least 3-5 intramuscular doses. The anthrax vaccine absorbed vaccine consists of complex cell-free culture filtrates of a toxigenic

Identifiers

PMID29263873
PMCPMC5627300
OpenAlexW2621035172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.